Clinical Trial Update: Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CG2001 for androgenetic alopecia in Chinese adult male participants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Drugs mentioned

• CG2001

Snippet

Sponsor: Beijing Dayspring Pharmaceutical Technology Co., Ltd | Conditions: Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA) | Phase 2 | Status: COMPLETED